Milestones :: Perspectives :: Research
Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
European Medicines Agency
News & Press Releases
News: Increase in vaccine manufacturing capacity for COVID-19 vaccines from BioNTech / Pfizer and Moderna (new)
CHMP, Last updated: 24/08/2021
Additional manufacturing site and scaled-up process for Comirnaty
CHMP has approved an additional manufacturing site for the production of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer. The site, located in Saint Rémy sur Avre, France, is operated by Delpharm and will manufacture finished product. The site will allow to provide approximately up to 51 million additional doses in 2021.
EMA has also approved a new manufacturing line at BioNTech’s manufacturing site in Marburg, Germany which increases the active substance manufacturing capacity by approximately 410 million doses in 2021.
Additional manufacturing site for Spikevax
CHMP has also approved an additional manufacturing site for the production of Spikevax, the COVID-19 vaccine developed by Moderna.
The site, located in Bloomington, Indiana, United States (US), is operated by Catalent. The site will perform finished product manufacturing.
In addition to the new manufacturing facility for this vaccine, CHMP has also approved several alternative sites responsible for batch control/testing and packaging of the finished product manufactured by Catalent…
European Centre for Disease Prevention and Control
Communicable disease threats report, 22-28 August, week 34
27 Aug 2021
No new digest content identified.